ImmunityBio, Inc. annual gross profit for fiscal 2025 was $112 million, an increase of 665.3% from $15 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gross Profit | $112M | $15M | $1M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit | $44M | $38M | $32M | $26M | $16M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IBRX metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow
All IBRX financial statements → Interactive IBRX charts →
About TickerBase · Data methodology & sources